Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H6O3.C6H15NO3 |
Molecular Weight | 287.3089 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN(CCO)CCO.OC(=O)C1=C(O)C=CC=C1
InChI
InChIKey=UEVAMYPIMMOEFW-UHFFFAOYSA-N
InChI=1S/C7H6O3.C6H15NO3/c8-6-4-2-1-3-5(6)7(9)10;8-4-1-7(2-5-9)3-6-10/h1-4,8H,(H,9,10);8-10H,1-6H2
Molecular Formula | C7H6O3 |
Molecular Weight | 138.1207 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H15NO3 |
Molecular Weight | 149.1882 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdfCurator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html
Sources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdf
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html
Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.
Originator
Sources: http://www.casinapioiv.va/content/dam/accademia/pdf/acta18/acta18-szczeklik.pdfhttps://books.google.ru/books?id=iUpwBAAAQBAJ&pg=PT83&lpg=PT83&dq=Methyl+salicylate+Auguste+Andr%C3%A9+Thomas+Cahours&source=bl&ots=nFDf2n2bpT&sig=wAKTDamdc7xWWgRxOrTeokeji8g&hl=ru&sa=X&ved=0ahUKEwj-q8769PzTAhVFfhoKHYEqDgkQ6AEIODAD#v=onepage&q=Methyl%20salicylate%20Auguste%20Andr%C3%A9%20Thomas%20Cahours&f=false
Curator's Comment: first isolated in 1843
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: http://www.drugbank.ca/drugs/DB00936 |
|||
Target ID: CHEMBL230 Sources: http://www.drugbank.ca/drugs/DB00936 |
|||
Target ID: CHEMBL2311236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26101955 |
1.48 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date2012 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date2012 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date2012 |
Doses
Dose | Population | Adverse events |
---|---|---|
30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
Other AEs: Redness, Scales... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Redness | 30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
|
Scales | 30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/9207195/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
major | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Salicylate attenuates gentamicin-induced ototoxicity. | 1999 Jul |
|
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats. | 2001 |
|
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries. | 2001 |
|
The solvent shells of cluster ions produced by direct electric field extraction from glycerol/water mixtures. | 2001 |
|
Hydroxyl radical adduct of 5-aminosalicylic acid: a potential marker of ozone-induced oxidative stress. | 2001 |
|
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
Unraveling regulatory networks in plant defense using microarrays. | 2001 |
|
Evaluation of insulin permeability and effects of absorption enhancers on its permeability by an in vitro pulmonary epithelial system using Xenopus pulmonary membrane. | 2001 Apr |
|
Isolation and preliminary characterization of the medium-chain fatty acid:CoA ligase responsible for activation of short- and medium-chain fatty acids in colonic mucosa from swine. | 2001 Feb |
|
Non-ionic micellar affinity capillary electrophoresis for analysis of interactions between micelles and drugs. | 2001 Feb |
|
Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay. | 2001 Feb |
|
Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals. | 2001 Feb 1 |
|
Characterization of PBZ1, a probenazole-inducible gene, in suspension-cultured rice cells. | 2001 Jan |
|
Increases in the mutation frequency at which fusidic acid-resistant Staphylococcus aureus arise with salicylate. | 2001 Jan |
|
Probenazole induces systemic acquired resistance in Arabidopsis with a novel type of action. | 2001 Jan |
|
Manipulation of salicylate content in Arabidopsis thaliana by the expression of an engineered bacterial salicylate synthase. | 2001 Jan |
|
Microfabrication of individual 200 microm diameter transdermal microconduits using high voltage pulsing in salicylic acid and benzoic acid. | 2001 Jan |
|
Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor kappaB-dependent transcription in human astrocytoma cells. | 2001 Jan |
|
A nuclear casein kinase 2 activity is involved in early events of transcriptional activation induced by salicylic acid in tobacco. | 2001 Jan |
|
Pathogen-induced expression of plant ATP: citrate lyase. | 2001 Jan 19 |
|
Combined cryotherapy/70% salicylic acid treatment for plantar verrucae. | 2001 Jan-Feb |
|
Quantitative analysis of hydroxyl radicals in the anterior optic nerve of the cat following transient ischemia. | 2001 Jan-Feb |
|
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus. | 2001 Jul 6 |
|
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways. | 2001 Mar |
|
Development of QSARs to investigate the bacterial toxicity and biotransformation potential of aromatic heterocylic compounds. | 2001 Mar |
|
Interference by bilirubin in salicylate measurement. | 2001 Mar |
|
Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs. | 2001 Mar |
|
Quantitative analysis of analgoantipyretics in dosage form using planar chromatography. | 2001 Mar |
|
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis. | 2001 Mar 1 |
|
ATR-FTIR spectroscopic investigations on the effect of solvents on the permeation of benzoic acid and salicylic acid through silicone membranes. | 2001 Mar 23 |
|
Use of methyl salicylate as a simulant to predict the percutaneous absorption of sulfur mustard. | 2001 Mar-Apr |
|
Asbestos causes apoptosis in alveolar epithelial cells: role of iron-induced free radicals. | 2001 May |
|
Anti-inflammatory and antipyretic effects of Trigonella foenum-graecum leaves extract in the rat. | 2001 May |
|
Measurement of free radical production by in vivo microdialysis during ischemia/reperfusion injury to skeletal muscle. | 2001 May 1 |
|
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum. | 2001 May 8 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/salicylic-acid.html
The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1811921
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:42:41 GMT 2023
by
admin
on
Fri Dec 15 15:42:41 GMT 2023
|
Record UNII |
H8O4040BHD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 352.20
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
||
|
CFR |
21 CFR 352.10
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000084670
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
H8O4040BHD
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
C84231
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
DTXSID4047969
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
C032758
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
H8O4040BHD
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
4442
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
TROLAMINE SALICYLATE
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
m11100
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB04990MIG
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
25213
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
2174-16-5
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
DB11079
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107288
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
38866
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | RxNorm | ||
|
218-531-3
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |